This guidance provides a data‐supported approach to the diagnostic, therapeutic, and
preventive aspects of nonalcoholic fatty liver disease (NAFLD) care. A “Guidance” document …

The prevalence of alcohol use disorder (AUD) has been steadily increasing over the past
decade. In parallel, alcohol-associated liver disease (ALD) has been increasing at an …

The prevalence of nonalcoholic fatty liver disease (NAFLD) is increasing rapidly worldwide
as the obese and diabetic populations increase, and it has been estimated to be 20–30% in …

Effective immunosupression management is central to achieving optimal outcomes in liver
transplant recipients. Current immunosuppression regimens and agents are highly effective …

This practice guideline has been approved by the American Association for the Study of
Liver Diseases and the American Society of Transplantation. These recommendations …

CONTEXT: Non-alcoholic fatty liver disease (NAFLD), hepatic manifestation of metabolic
syndrome, has been considered the most common liver disease nowadays, which is also …

The evolution of metabolic and cardiovascular disease (CVD) complications after liver
transplantation (LT) is poorly characterized. We aim to illustrate the prevalence of obesity …

Non-alcoholic fatty liver disease (NAFLD) is an important health problem worldwide. NAFLD
encompasses a histological spectrum ranging from bland liver steatosis to severe …

Non-alcoholic fatty liver disease (NAFLD) is currently the fastest growing indication to liver
transplantation (LT) in Western Countries, both for end stage liver disease and …

Objectives Recent improvements in surgical technique have extended the indications for
liver resection. The aims of this study were to assess whether this extension is associated …